Previously, Yong et al. (2019) found that breast cancer patients with high CD155 expression had poor OS rates, while Sun et al. (2020) showed that CD155 expression was an independent risk factor for lung adenocarcinoma and that patients with high CD155 expression presented shorter OS and PFS. This evidence concerns the gene PVR and breast carcinoma.